Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Hagberg

Showing results (81-90 of 132) with videos related to

Pageof 14
Sort By:
Trials|September 16, 2020
Long-term physical activity on prescription intervention for patients with insufficient physical activity level-a randomized controlled trialStefan Lundqvist, Mats Börjesson, Åsa Cider, et al.
The Journal of Infectious Diseases|February 6, 2018
Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?Peter D Burbelo, Richard W Price, Lars Hagberg, et al.
Plos One|October 24, 2014
PXL01 in sodium hyaluronate for improvement of hand recovery after flexor tendon repair surgery: randomized controlled trialMonica E Wiig, Lars B Dahlin, Jan Fridén, et al.
The Journal of Infectious Diseases|November 6, 2010
HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatmentArvid Edén, Dietmar Fuchs, Lars Hagberg, et al.
The Journal of Infectious Diseases|December 17, 2013
An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapyViktor Dahl, Magnus Gisslen, Lars Hagberg, et al.
Journal of Neurology|April 11, 2007
CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegenerationSahra Abdulle, Asa Mellgren, Bruce J Brew, et al.
AIDS Research and Human Retroviruses|August 12, 2003
pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapyEleonor Brandin, Lena Lindborg, Katarina Gyllensten, et al.
Journal of Neurology|October 12, 2012
Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infectionsJan Jessen Krut, Henrik Zetterberg, Kaj Blennow, et al.
AIDS (London, England)|July 14, 2018
Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatmentGustaf Ulfhammer, Arvid Edén, Åsa Mellgren, et al.
AIDS Research and Therapy|June 8, 2010
Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infectionLars Hagberg, Paola Cinque, Magnus Gisslen, et al.
Pageof 14

Showing results (81-90 of 132) with videos related to

Sort By:
Pageof 14
Trials|September 16, 2020
Long-term physical activity on prescription intervention for patients with insufficient physical activity level-a randomized controlled trialStefan Lundqvist, Mats Börjesson, Åsa Cider, et al.
The Journal of Infectious Diseases|February 6, 2018
Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir?Peter D Burbelo, Richard W Price, Lars Hagberg, et al.
Plos One|October 24, 2014
PXL01 in sodium hyaluronate for improvement of hand recovery after flexor tendon repair surgery: randomized controlled trialMonica E Wiig, Lars B Dahlin, Jan Fridén, et al.
The Journal of Infectious Diseases|November 6, 2010
HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatmentArvid Edén, Dietmar Fuchs, Lars Hagberg, et al.
The Journal of Infectious Diseases|December 17, 2013
An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapyViktor Dahl, Magnus Gisslen, Lars Hagberg, et al.
Journal of Neurology|April 11, 2007
CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegenerationSahra Abdulle, Asa Mellgren, Bruce J Brew, et al.
AIDS Research and Human Retroviruses|August 12, 2003
pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapyEleonor Brandin, Lena Lindborg, Katarina Gyllensten, et al.
Journal of Neurology|October 12, 2012
Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infectionsJan Jessen Krut, Henrik Zetterberg, Kaj Blennow, et al.
AIDS (London, England)|July 14, 2018
Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatmentGustaf Ulfhammer, Arvid Edén, Åsa Mellgren, et al.
AIDS Research and Therapy|June 8, 2010
Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infectionLars Hagberg, Paola Cinque, Magnus Gisslen, et al.
Pageof 14